Neuroendocrine tumors of the larynx account for<1% of all laryngeal cancers. Laryngeal small cell carcinomas of the neuroendocrine type (SCNC) account for <0.5% of all laryngeal tumors. We report two cases of 65-and 75-year old men with small cell carcinoma of the supraglottic larynx. The patients were treated with induction chemotherapy (cisplatin-etoposide) and chemoradiotherapy (cisplatin-etoposide). The first patient was alive until 26 months from diagnosis. However, multiple brain metastases developed in the second patient, and he died 16 months after diagnosis. Small cell neuroendocrine carcinomas are very aggressive neoplasms. A combination of platinum-based chemotherapy and radiotherapy is the mainstay of the treatment for SCNC, which is considered to be a systemic disease.